SCHEMBL20549518

SCHEMBL20549518

COC(=O)c1cc2cc(F)c(Br)c3c2n(c1=O)C(C)C3

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.33
HPGD P15428 5/20 0.33
TSHR P16473 4/20 0.33
HSD17B10 Q99714 3/20 0.33
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA3 P34903 1/20 0.32
KDM4E B2RXH2 2/20 0.32
P2RX7 Q99572 2/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
LMNA P02545 2/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 2/20 0.30
KCNH2 Q12809 1/20 0.30
SCN5A Q14524 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
SOS1 Q07889 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20549817 0.90 ALDH1A1 (0.34) ALDH1A1HPGDTSHRHSD17B10GABRA1
SCHEMBL20549787 0.78 TLR2 (0.38) ALDH1A1KDM4ELMNAKMT2A
SCHEMBL20549485 0.77 SCN5A (0.41) ALDH1A1KDM4ELMNAKCNH2SCN5A
SCHEMBL17494415 0.76 KCNH2 (0.39) ALDH1A1HPGDKDM4EMAPTKMT2A
SCHEMBL20549456 0.70 KDM4E (0.38) ALDH1A1HPGDKDM4ELMNAMAPT
SCHEMBL20549436 0.69 TLR2 (0.38) ALDH1A1KDM4ELMNAKMT2A
SCHEMBL20549418 0.68 KCNH2 (0.48) ALDH1A1HPGDHSD17B10KDM4EKMT2A
SCHEMBL20549371 0.68 SCN5A (0.38) KDM4ELMNAKCNH2SCN5A
SCHEMBL20549899 0.68 TOP2A (0.43) ALDH1A1HPGDHSD17B10KDM4ELMNA
SCHEMBL20549568 0.68 TLR2 (0.43) ALDH1A1KDM4ELMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180318311-A1 TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2018-11-08 US disclosed
WO-2018203302-A1 TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS NOVARTIS AG (CH) 2018-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180318311-A1 TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS TOP1, TOP2A, TOP2B ALDH1A1 1696/4885HPGD 397/4885TSHR 4761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.